福泰制药
VRTX
查看详细走势图
477.910USD
+3.740+0.79%
收盘 01/28, 16:00（美东）报价延迟15分钟
121.37B总市值
33.40市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+0.79%
5天
+3.64%
1月
+3.24%
6月
+3.71%
今年开始到现在
+5.42%
1年
+8.45%
查看详细走势图
TradingKey 福泰制药股票评分
单位: USD 更新时间: 2026-01-28操作建议
福泰制药当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在药品行业排名6/159位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价503.63。中期看，股价处于上升通道。近一个月，市场表现较强，技术面和基本面综合得分较高，较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
福泰制药评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看好
福泰制药亮点
亮点风险
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
业绩高增长
公司营业收入稳步增长，连续3年增长23.40%
业绩转亏
公司业绩转亏，最新年度亏损美元
估值高估
公司最新PE估值33.40，处于3年历史高位
机构减仓
最新机构持股248.51M股，环比减少2.74%
CI 精选加拿大股票基金持仓
明星投资者CI 精选加拿大股票基金持仓，最新持仓市值5.30K
活跃度增加
近期活跃度增加，过去20天平均换手率0.81
分析师目标
根据
33
位分析师
买入
评级
503.632
目标均价
+7.52%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
福泰制药新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
福泰制药简介
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
公司代码VRTX
公司福泰制药
CEOKewalramani (Reshma)
网址https://www.vrtx.com/
相关品种
